Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) EPS (Basic) (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed EPS (Basic) for 16 consecutive years, with -$0.51 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 17.74% to -$0.51 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.4 through Dec 2025, down 12.0% year-over-year, with the annual reading at -$1.41 for FY2025, 14.63% down from the prior year.
  • EPS (Basic) hit -$0.51 in Q4 2025 for Perspective Therapeutics, down from -$0.35 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.01 in Q1 2023 to a low of -$0.72 in Q4 2023.
  • Historically, EPS (Basic) has averaged -$0.21 across 5 years, with a median of -$0.19 in 2024.
  • Biggest YoY gain for EPS (Basic) was 200.0% in 2023; the steepest drop was 3900.0% in 2023.
  • Year by year, EPS (Basic) stood at -$0.01 in 2021, then tumbled by 300.0% to -$0.04 in 2022, then plummeted by 1700.0% to -$0.72 in 2023, then grew by 13.89% to -$0.62 in 2024, then increased by 17.74% to -$0.51 in 2025.
  • Business Quant data shows EPS (Basic) for CATX at -$0.51 in Q4 2025, -$0.35 in Q3 2025, and -$0.29 in Q2 2025.